ClinicalTrials.gg

Program

ARM011

A development code.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by TriArm Therapeutics (Taiwan).

Furthest: phase 1, since Jul 4, 20251 company-led study, 1 open or runningNext primary completion: Apr 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TriArm Therapeutics (Taiwan)11 open or runningphase 1since Jul 4, 2025Jul 4, 2025Apr 1, 2028phase 1 · NCT07066397

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 4, 2025First study: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT07066397 · 12 planned · Taiwan

Ahead

  1. Apr 1, 2028Primary completion: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07066397

TargetBeta

CD19 →read by rule
“ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process”study text, by rule · the study

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07066397Precursor Cell Lymphoblastic Leukemia-Lymphoma · Taiwan1RecruitingApr 1, 202812

How it is read

Names in the registry

  • “ARM011”, 1 entry

Codes read as this program: ARM011.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.